Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 20/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 6/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15768257 | 1.00 | CHRM3 (0.39) | CHRM3CHRM5CHRM1CHRM2 | |
| SCHEMBL15768255 | 1.00 | CHRM3 (0.39) | CHRM3CHRM5CHRM1CHRM2 | |
| SCHEMBL14694554 | 0.90 | CHRM3 (0.41) | CHRM3CHRM5CHRM1CHRM2 | |
| SCHEMBL14694556 | 0.90 | CHRM3 (0.41) | CHRM3CHRM5CHRM1CHRM2 | |
| SCHEMBL14694557 | 0.90 | CHRM3 (0.41) | CHRM3CHRM5CHRM1CHRM2 | |
| SCHEMBL15772087 | 0.88 | NPC1 (0.39) | CHRM3 | |
| SCHEMBL15772084 | 0.88 | NPC1 (0.39) | CHRM3 | |
| SCHEMBL15772086 | 0.88 | NPC1 (0.39) | CHRM3 | |
| SCHEMBL14694649 | 0.87 | CHRM3 (0.42) | CHRM3CHRM5CHRM1CHRM2 | |
| SCHEMBL14694648 | 0.87 | CHRM3 (0.42) | CHRM3CHRM5CHRM1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8980913-B2 | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-03-17 | — | — | US | disclosed |
| US-20140163066-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140163066-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | ADRB2, ADRB1, ADRA2B | CHRM3 11/4885CHRM5 21/4885CHRM1 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.